Medivir AB (STO:MVIRB) on Wednesday reported loss after tax of SEK39.8m, or SEK1.48 per share, for the second quarter 2016, from April 2016 to June 2016.

This was a decline over profit after tax of SEK64.1m, or EPS of SEK2.19, in Q2 2015.

Net turnover for the quarter totalled SEK81.3m, of which SEK24.2m comprised of royalties for simeprevir. This was in comparison with net turnover of SEK245.8m in Q2 2015, of which SEK165.6m comprised royalties for simeprevir.

For the quarter, revenues from Medivir's own pharmaceutical sales totalled SEK50.1m, of which SEK5.6m were from sales of OLYSIO and SEK44.5m were from sales of other pharmaceuticals.

In comparison, revenues from Medivir's own pharmaceutical sales for Q2 2015 totalled SEK55.1m, of which SEK13.2m were from sales of OLYSIO and SEK41.9m were from sales of other pharmaceuticals.

Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases.

(EUR1.00=SEK9.48)